



IFW

ATTORNEY'S DOCKET HIR-117  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the application of:                 )         Group Art Unit:  
  )  
Hiroharu ARAKAWA, et al.                 )  
  )         Examiner: Unknown  
Serial No. 10/509,061                     )  
  )  
Filed:         September 24, 2004         )

For: COMBINED USE OF ANTITUMOR INDOLOPYRROLOCARBAZOLE DERIVATIVE  
AND OTHER ANTITUMOR AGENT

# INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[**NOTE:** One only of items a, b, c, and d must be checked.]

- ☒ ] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- ☐ ] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311.

The enclosed statement is accompanied by [check one]:

- ☐ i. a certification in part (e) below as specified in 37 C.F.R. §1.97(e), or
- ☐ ii. a check in the amount of \$ \_\_\_\_\_ required by 37 C.F.R. §1.17(p).
- ☐ c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311, but before payment of the issue fee.

PETITION: It is requested that the information being submitted be considered. [NOTE: If box (c) is checked, the following two boxes must be checked.]

☐ PETITION FEE: A check for \$180.00 required by 37 CFR \$1.17(p), is enclosed.

☐ CERTIFICATION is attended to in box (e) below.

☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. \$1.97(i), for placement in the file.

☐ e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. \$1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

☒ f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 19-1980.

Respectfully submitted,

**SHERMAN AND ASSOCIATES**

Attorney for Applicants

Robert L. Haines

Reg. No. 35,533

**SHERMAN AND ASSOCIATES**

415 N. Alfred Street

Alexandria, Virginia 22314

703-549-2282



HIR-117

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Hiroharu ARAKAWA, et al.

Serial No.: 10/509,061

Group:

Filed: September 24, 2004

Examiner:

FOR: COMBINED USE OF ANTITUMOR INDOLOPYRROLOCARBAZOLE DERIVATIVE  
AND OTHER ANTITUMOR AGENT

Date: April 5, 2006

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with their obligation under 37 C.F.R.  
§1.56, Applicants would like to call the Examiner's attention to  
the documents listed on the attached forms SB-08A


Applicants note that all of the documents listed are  
cited in the Official Search Report issued in Applicants'  
corresponding application before the National Centre of the  
Intellectual Property "Sakpatenti" of Georgia, a copy of which is  
enclosed.

English abstracts of the cited Russian patent documents are provided herewith. Also submitted are copies of WO9807433 and U.S. Patent 6,436,951 which correspond to RU2167880 and RU2220144, respectively. Applicants can find no corresponding published application or patent in English for RU2255089. Applicants further note that the cited documents WO 01/87307 and EP 545195 have been previously provided with the Information Disclosure Statements filed January 27, 2005 and October 20, 2004, respectively.

It is noted that the Search Report identifies the Russian patent documents as defining the general state of the art and are not considered to be of particular relevance. Accordingly, they are provided herewith for the examiner's convenience.

Applicants are not aware at this time of any other prior art which could be considered to be relevant to the present application.

Respectfully submitted,

  
Attorney for Applicants  
Robert L. Haines  
Reg. No. 35,533

SHERMAN & ASSOCIATES  
P.O. BOX 788  
Alexandria, Virginia 22313  
(703) 549-2282

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*